Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$13.89 -3.7%	$16.24	$3.25 ▼ $21.48	$386.98M	1.18	272,748 shs	646,964 shs
ORIC Oric Pharmaceuticals	$11.18 +1.8%	$8.58	$3.90 ▼ $14.67	$935.76M	1.54	786,205 shs	551,855 shs
ORMP Oramed Pharmaceuticals	$2.11 +1.0%	$2.18	$1.82 ▼ $3.09	$85.38M	1.59	140,854 shs	27,865 shs
VERV Verve Therapeutics	$11.02	$7.69	$2.86 ▼ $11.41	$982.36M	2.23	2.48 million shs	2.19 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	-3.74%	-11.92%	-1.98%	-3.14%	+286.91%
ORIC Oric Pharmaceuticals	+1.82%	+2.57%	+18.81%	+134.38%	+1.73%
ORMP Oramed Pharmaceuticals	+0.96%	-2.76%	-2.31%	-1.86%	-17.58%
VERV Verve Therapeutics	0.00%	-0.63%	+75.76%	+140.09%	+40.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETON Eton Pharmaceuticals	1.9414 of 5 stars	3.5	1.0	0.0	2.0	1.7	0.6
ORIC Oric Pharmaceuticals	4.4692 of 5 stars	4.5	1.0	4.4	1.5	3.3	0.6
ORMP Oramed Pharmaceuticals	1.0266 of 5 stars	0.0	4.0	0.0	2.7	0.8	0.6
VERV Verve Therapeutics	3.0154 of 5 stars	4.2	3.0	0.0	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	113.58% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$18.57	66.11% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
VERV Verve Therapeutics	2.33	Hold	$14.57	32.23% Upside

Current Analyst Ratings Breakdown

Latest ORMP, ETON, VERV, and ORIC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETON Eton Pharmaceuticals	$39.01M	9.55	N/A	N/A	$0.94 per share	14.78
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A
ORMP Oramed Pharmaceuticals	$1.34M	64.32	N/A	N/A	$3.61 per share	0.58
VERV Verve Therapeutics	$32.33M	30.38	N/A	N/A	$5.83 per share	1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	27.78	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.44	N/A	N/A	N/A	N/A	-11.34%	-10.73%	8/13/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest ORMP, ETON, VERV, and ORIC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	ORMP Oramed Pharmaceuticals	-$0.01	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ORMP Oramed Pharmaceuticals	-$0.03	-$0.19	-$0.16	-$0.19	N/A	$2.00 million
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/5/2025	Q1 2025	ORIC Oric Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETON Eton Pharmaceuticals	1.23	1.97	1.43
ORIC Oric Pharmaceuticals	N/A	12.00	12.00
ORMP Oramed Pharmaceuticals	N/A	23.94	23.94
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETON Eton Pharmaceuticals	27.86%
ORIC Oric Pharmaceuticals	95.05%
ORMP Oramed Pharmaceuticals	12.73%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
ETON Eton Pharmaceuticals	16.03%
ORIC Oric Pharmaceuticals	6.82%
ORMP Oramed Pharmaceuticals	13.70%
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
ORIC Oric Pharmaceuticals	80	85.22 million	79.41 million	Optionable
ORMP Oramed Pharmaceuticals	10	40.85 million	35.25 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.40 million	Optionable

ORMP, ETON, VERV, and ORIC Headlines

Recent News About These Companies

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing

July 16 at 7:41 PM | thepharmaletter.comT

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)

...

July 15 at 4:27 PM | marketbeat.com

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

July 14 at 12:44 PM | msn.com

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

July 14 at 2:41 AM | msn.com

Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.

July 13, 2025 | hindustantimes.comH

Experimental treatment for high cholesterol edits DNA in the body to reduce LDL

July 11, 2025 | msn.com

Verve Therapeutics Inc News (VERV) - Investing.com

July 4, 2025 | investing.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Hold" by Analysts

July 3, 2025 | marketbeat.com

June’s Busy Buyout Binge Bolsters M&A Stats for H1

July 1, 2025 | biospace.comB

BMO Capital Markets Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 28, 2025 | marketbeat.com

BMO Capital Markets Reiterates Market Perform Rating for Verve Therapeutics (NASDAQ:VERV)

June 27, 2025 | marketbeat.com

VERV Verve Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Eli Lilly's Strategic Acquisition of Verve Therapeutics

June 24, 2025 | pharmiweb.comP

GAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

June 24, 2025 | marketbeat.com

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

June 23, 2025 | insidermonkey.com

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

June 20, 2025 | fool.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

June 20, 2025 | globenewswire.com

Q2 Earnings Forecast for VERV Issued By Lifesci Capital

June 19, 2025 | marketbeat.com

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

June 19, 2025 | insidenova.comI

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

June 19, 2025 | msn.com

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

June 18, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, ETON, VERV, and ORIC Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

$13.89 -0.54 (-3.74%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$13.98 +0.09 (+0.68%)

As of 07/16/2025 06:38 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Oric Pharmaceuticals NASDAQ:ORIC

$11.18 +0.20 (+1.82%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$11.16 -0.02 (-0.13%)

As of 07/16/2025 06:49 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.11 +0.02 (+0.96%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.12 +0.01 (+0.24%)

As of 07/16/2025 04:58 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Verve Therapeutics NASDAQ:VERV

$11.02 0.00 (0.00%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$11.02 0.00 (-0.05%)

As of 07/16/2025 07:21 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time